Reported 1 day ago
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is focusing on achieving $1 billion in sales for its drug Amtagvi (lifileucel) as part of its growth strategy, which includes expanding the drug's use to treat non-small cell lung cancer and endometrial cancer. The initiative follows a successful Phase 3 study showing promising results for melanoma treatment. Additionally, the company plans to cut over $100 million in operating costs while enhancing operational efficiency to improve profit margins.
Source: YAHOO